| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
85,450,000 |
| Market
Cap: |
102.54(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.14 - $12.75 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Hepion Pharmaceuticals is a biopharmaceutical company focused on the development of drug therapy for treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Co.'s cyclophilin inhibitor, CRV431, is being developed to address these pathologies. CRV431 is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease. CRV431 additionally shows in vitro antiviral activity towards hepatitis B, C, and D viruses which also trigger liver disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
11,200 |
11,200 |
| Total Buy Value |
$0 |
$0 |
$49,791 |
$49,791 |
| Total People Bought |
0 |
0 |
2 |
2 |
| Total Buy Transactions |
0 |
0 |
6 |
6 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wijngaard Peter |
Director |
– • – |
2023-11-27 |
4 |
B |
$3.05 |
$7,625 |
D/D |
2,500 |
9,501 |
2.39 |
-14% |
|
| Wijngaard Peter |
Director |
– • – |
2023-11-24 |
4 |
B |
$3.09 |
$7,725 |
D/D |
2,500 |
7,001 |
2.39 |
-20% |
|
| Wijngaard Peter |
Director |
– • – |
2023-09-19 |
4 |
B |
$5.64 |
$5,640 |
D/D |
1,000 |
4,501 |
2.39 |
-68% |
|
| Foster Robert T |
CEO and Director |
• • – |
2023-09-18 |
4 |
B |
$5.60 |
$8,960 |
D/D |
1,600 |
50,470 |
2.81 |
-67% |
|
| Wijngaard Peter |
Director |
– • – |
2023-09-15 |
4 |
B |
$5.37 |
$11,201 |
D/D |
2,000 |
3,501 |
2.39 |
-63% |
|
| Foster Robert T |
CEO,CSO and Director |
• • – |
2023-09-15 |
4 |
B |
$5.40 |
$8,640 |
D/D |
1,600 |
48,870 |
2.81 |
-63% |
|
| Cavan John T |
Chief Financial Officer |
• – – |
2021-02-18 |
4 |
B |
$2.00 |
$20,000 |
D/D |
10,000 |
14,800 |
2.74 |
-6% |
|
| Foster Robert T |
CEO and Director |
• • – |
2021-02-18 |
4 |
B |
$2.00 |
$40,000 |
D/D |
20,000 |
45,259 |
2.81 |
-6% |
|
| Wijngaard Peter |
Director |
– • – |
2021-02-16 |
4 |
B |
$2.20 |
$22,000 |
D/D |
10,000 |
30,000 |
2.39 |
2% |
|
| Wijngaard Peter |
Director |
– • – |
2020-12-18 |
4 |
B |
$1.91 |
$38,200 |
D/D |
20,000 |
20,000 |
2.39 |
-11% |
|
| Foster Robert T |
CEO and Director |
• • – |
2020-12-08 |
4 |
B |
$1.58 |
$39,418 |
D/D |
25,000 |
25,259 |
2.81 |
-10% |
|
| Brancaccio John P |
Director |
– • – |
2020-12-02 |
4 |
B |
$1.53 |
$10,710 |
D/D |
7,000 |
7,008 |
2.39 |
11% |
|
| Jacob Gary S |
Director |
– • – |
2020-12-01 |
4 |
B |
$1.66 |
$19,920 |
D/D |
12,000 |
12,059 |
2.39 |
4% |
|
| Cavan John T |
Chief Financial Officer |
• – – |
2020-11-25 |
4 |
B |
$1.62 |
$7,290 |
D/D |
4,500 |
4,800 |
2.74 |
16% |
|
| Garlikov Donald E |
10% Owner |
– – • |
2019-03-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,320,000 |
|
- |
|
| Sapirstein James |
Chief Executive Officer |
• • – |
2018-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
322,092 |
492,819 |
|
- |
|
| Foster Robert T |
Chief Scientific Officer |
• – – |
2018-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
100,654 |
144,736 |
|
- |
|
| Cavan John T |
CFO |
• – – |
2018-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
101,221 |
167,947 |
|
- |
|
| Cavan John T |
CFO |
• – – |
2017-07-06 |
4 |
A |
$0.00 |
$0 |
D/D |
46,726 |
66,726 |
|
- |
|
| Sapirstein James |
Chief Executive Officer |
• • – |
2017-07-06 |
4 |
A |
$0.00 |
$0 |
D/D |
141,061 |
170,727 |
|
- |
|
| Foster Robert T |
Chief Scientific Officer |
• – – |
2017-07-06 |
4 |
A |
$0.00 |
$0 |
D/D |
44,082 |
44,082 |
|
- |
|
| Sullivan-Bolyai John Z |
Chief Medical Officer |
• – – |
2017-07-06 |
4 |
A |
$0.00 |
$0 |
D/D |
58,681 |
58,681 |
|
- |
|
| Cavan John T |
CFO |
• – – |
2017-06-20 |
4 |
B |
$0.65 |
$13,000 |
D/D |
20,000 |
20,000 |
2.74 |
- |
|
| Sapirstein James |
Chief Executive Officer |
• • – |
2016-10-27 |
4 |
OE |
$1.50 |
$24,999 |
D/D |
16,666 |
29,666 |
|
- |
|
| Cerrone Gabriel |
10% Owner |
– – • |
2016-08-17 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,105,433 |
|
- |
|
30 Records found
|
|
Page 1 of 2 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.05 (4.35%) 
